IGC Pharma, Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a IGC research report →
Companyigcpharma.com
IGC Pharma, Inc. is a clinical-stage pharmaceutical company that is focused on Alzheimer's disease, developing innovative solutions to address this devastating illness. It has two investigational drug assets targeting Alzheimer's disease: IGC-AD1, which is in a Phase 2 clinical trial as a treatment for agitation in dementia due to Alzheimer's and TGR-63 that is in pre-clinical development.
- CEO
- Ram Mukunda
- IPO
- 2006
- Employees
- 67
- HQ
- Potomac, MD, US
Price Chart
Valuation
- Market Cap
- $27.76M
- P/E
- -4.08
- P/S
- 23.41
- P/B
- 4.36
- EV/EBITDA
- -2.79
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 29.68%
- Op Margin
- -860.29%
- Net Margin
- -552.11%
- ROE
- -94.51%
- ROIC
- -161.64%
Growth & Income
- Revenue
- $1.27M · 0.00%
- Net Income
- $-7,121,000 · 0.00%
- EPS
- $-0.09 · 0.00%
- Op Income
- $-7,446,000
- FCF YoY
- 0.00%
Performance & Tape
- 52W High
- $0.50
- 52W Low
- $0.24
- 50D MA
- $0.30
- 200D MA
- $0.33
- Beta
- 0.50
- Avg Volume
- 1.10M
Get TickerSpark's AI analysis on IGC
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| Apr 1, 26 | PRINS RICHARD K | other | 70,000 |
| Apr 1, 26 | PRINS RICHARD K | other | 100,000 |
| Apr 1, 26 | PRINS RICHARD K | other | 70,000 |
| Apr 1, 26 | PRINS RICHARD K | other | 100,000 |
| Apr 1, 26 | Mukunda Ram | other | 323,077 |
| Apr 1, 26 | Mukunda Ram | other | 333,333 |
| Apr 1, 26 | Mukunda Ram | other | 33,332 |
| Apr 1, 26 | Mukunda Ram | other | 16,667 |
| Apr 1, 26 | Mukunda Ram | other | 323,077 |
| Apr 1, 26 | Mukunda Ram | other | 33,332 |
Our IGC Coverage
We haven't published any research on IGC yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate IGC Report →